文献速递慢阻肺

COPD生物标志物与临床结局:系统综述与荟萃分析

Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis.
PubMed 文献 · Thorax · 2019-01-07

该系统综述与荟萃分析检索至2018年8月,纳入61项研究,评估稳定期COPD患者多种生物标志物与临床结局的关联。结果显示6分钟步行距离缩短及心率、纤维蛋白原、C反应蛋白、白细胞计数升高与死亡风险增加相关,部分标志物亦与急性加重和住院相关。

要点

  • 6分钟步行距离每增加50米,死亡风险降低(汇总HR 0.80)。
  • 纤维蛋白原、CRP、白细胞计数升高与死亡风险增加相关。
  • 肌肉骨骼指标与结局的关联研究较少,需进一步探索。

核心结论

  • 6分钟步行距离、心率、CRP、纤维蛋白原和白细胞计数与稳定期COPD患者临床结局相关。

研究设计与样本

  • 系统检索电子数据库至2018年8月,纳入61项研究,遵循MOOSE和PRISMA指南进行荟萃分析。

主要发现

  • 6分钟步行距离每增加50米,死亡汇总HR为0.80(95%CI 0.73-0.89)。
  • 心率每升高10次/分,死亡汇总HR为1.10(95%CI 1.02-1.18)。
  • 纤维蛋白原每增加两倍,死亡汇总HR为3.13(95%CI 2.14-4.57)。
  • CRP每增加两倍,死亡汇总HR为1.17(95%CI 1.06-1.28)。
  • 白细胞计数每增加两倍,死亡汇总HR为2.07(95%CI 1.29-3.31)。

临床怎么用

  • 可利用6分钟步行距离、心率、CRP、纤维蛋白原和白细胞计数辅助评估稳定期COPD患者的预后风险。

局限性

  • 评估肌肉骨骼指标与结局关联的研究较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conventional measures to evaluate COPD may fail to capture systemic problems, particularly musculoskeletal weakness and cardiovascular disease. Identifying these manifestations and assessing their association with clinical outcomes (ie, mortality, exacerbation and COPD hospital admission) is of increasing clinical importance. OBJECTIVE: To assess associations between 6 min walk distance (6MWD), heart rate, fibrinogen, C reactive protein (CRP), white cell count (WCC), interleukins 6 and 8 (IL-6 and IL-8), tumour necrosis factor-alpha, quadriceps maximum voluntary contraction, sniff nasal inspiratory pressure, short physical performance battery, pulse wave velocity, carotid intima-media thickness and augmentation index and clinical outcomes in patients with stable COPD. METHODS: We systematically searched electronic databases (August 2018) and identified 61 studies, which were synthesised, including meta-analyses to estimate pooled HRs, following Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: Shorter 6MWD and elevated heart rate, fibrinogen, CRP and WCC were associated with higher risk of mortality. Pooled HRs were 0.80 (95% CI 0.73 to 0.89) per 50 m longer 6MWD, 1.10 (95% CI 1.02 to 1.18) per 10 bpm higher heart rate, 3.13 (95% CI 2.14 to 4.57) per twofold increase in fibrinogen, 1.17 (95% CI 1.06 to 1.28) per twofold increase in CRP and 2.07 (95% CI 1.29 to 3.31) per twofold increase in WCC. Shorter 6MWD and elevated fibrinogen and CRP were associated with exacerbation, and shorter 6MWD, higher heart rate, CRP and IL-6 were associated with hospitalisation. Few studies examined associations with musculoskeletal measures. CONCLUSION: Findings suggest 6MWD, heart rate, CRP, fibrinogen and WCC are associated with clinical outcomes in patients with stable COPD. Use of musculoskeletal measures to assess outcomes in patients with COPD requires further investigation. TRIAL REGISTRATION NUMBER: CRD42016052075.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019. PMID: 30617161. doi:10.1136/thoraxjnl-2018-211855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。